Pricing Log in Create free account
Friday 6 November 2026 Export ELMD’s income statement to Excel — free account

Electromed, Inc.

ELMD Healthcare Medical Devices

Electromed, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $73.8 million, up 15.3% from fiscal 2025.

Revenue
+11.6%
EPS
+57.7%
Free cash flow
−25.2%

Quarter to June 2026, against a year earlier

27.00 0.23 +0.86%
Market cap
$221.8M
P/E
19.4×
Fwd P/E
18.6×
Dividend yield
—
F-score
8/9
Altman Z
20.30
Beneish M
−2.20
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 2.20
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — 1 2 — — — — —
Insider Ownership 17.01%

Capital & Financial Ratios $m

Size
Market Cap 221.84
Revenue ttm 73.78
Net income ttm 11.30
Free cash flow ttm 8.37
Net debt Q (20.45)
Valuation
P/E 19.39
Forward P/E 18.60
Price / sales 2.98
Forward P/S Powerpack
Price / FCF 26.26
Price / book 4.07
Financial health
Current ratio Q 4.69 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q 1.84
Growth
Revenue growth Q +11.64% (above 0%: growing)
Operating income growth Q +25.82% (above 0%: growing)
EPS, this year +11.92%
EPS, next year A +16.15% (at or above 15%: strong)
Revenue, next year A +12.71% (at or above 10%: strong)
EPS, past 5 yrs +36.94% (at or above 15%: strong)
EPS, next 5 yrs A +17.15% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.7×, against a ten-year median of 2.1×; over the ten years it ranged from 0.5× in 2016 to 4.6× in 2025.
P/E against its own 10 years 9.39%
10-year low 10-year high
P/S against its own 10 years 79.68%
10-year low 10-year high
P/B against its own 10 years 80.97%
10-year low 10-year high
EV/Sales against its own 10 years 78.95%
10-year low 10-year high
EV/FCF against its own 10 years 42.17%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 2026
Cash 7 16 15 20
Receivables 24 23 25 31
Inventory 4 4 3 4
Other 0 1 1 1
38 44 45 57
2023 2024 2025 2026
Payables 1 1 3 3
ST’ Debt — — — —
Other 3 2 3 4
8 8 10 12

Compound Annual Growth %

10y 5y 3y
Sales 12.37% 15.59% 15.35%
Cash Flow 16.13% 25.72% 94.43%
Earnings 17.71% 36.76% 52.83%
Book Value 12.68% 10.74% 12.74%

Earnings Trends EPS, adjusted, against the consensus

Q4 FY26 Estimate 0.32 Actual 0.39

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q1 FY26 0.22 0.25 Beat by 0.03
Q2 FY26 0.27 0.32 Beat by 0.05
Q3 FY26 0.26 0.35 Beat by 0.09
Q4 FY26 0.32 0.39 Beat by 0.07

EPS $

Sep Dec Mar Jun Year
’26 — — — — —
’26 0.25 0.32 0.35 0.39 1.30
’25 0.16 0.22 0.21 0.25 0.85
’24 0.02 0.19 0.17 0.20 0.58
’23 0.01 0.11 0.12 0.12 0.36
’22 0.05 0.10 0.07 0.04 0.26
’21 0.06 0.13 0.03 0.04 0.27
Fiscal quarters ending in the months shown.

Revenue $m

Sep Dec Mar Jun Year
’26 — — — — —
’26 17 19 19 19 74
’25 15 16 16 17 64
’24 12 14 14 15 55
’23 11 12 12 14 48
’22 10 10 10 11 42
’21 8 9 9 9 36
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Sep Dec Mar Jun Year
’26 — — — — —
’26 0 3 3 3 10
’25 2 3 2 4 11
’24 0 3 1 4 9
’23 (2) 1 1 1 1
’22 (1) 0 0 (1) (1)
’21 1 1 1 1 3
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Sep Dec Mar Jun Year
’26 — — — — —
’26 0 2 3 3 8
’25 2 3 2 4 11
’24 0 3 1 4 9
’23 (2) 1 0 1 0
’22 (1) 0 0 (1) (2)
’21 1 1 1 1 3
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to June

Ten-year view Analyst estimates Powerpack
Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Trend 10 yrs 2027e 2028e 2029e Next 3/yr
Income, $m
Income, $m Revenue 26 28 31 32 36 42 48 55 64 74 +12.4% 83 92 103 +11.8%
Gross margin, % 79.53 76.92 76.19 77.61 76.36 75.47 75.98 76.26 78.08 78.54 (1.0) pt
EBT 4 3 3 5 3 3 4 7 10 14 +16.9%
EBT margin, % 13.61 9.65 9.33 16.13 8.86 7.19 8.50 12.86 16.07 19.46 +5.9 pt
Net income 2 2 2 4 2 2 3 5 8 11 +19.8%
Per share, $
Per share, $ Revenue 3.17 3.45 3.77 3.86 4.17 4.92 5.68 6.39 7.57 8.93 +12.2%
Earnings 0.27 0.23 0.24 0.50 0.28 0.27 0.37 0.60 0.89 1.37 +19.8%
Cash flow 0.15 0.30 0.31 0.50 0.36 (0.08) 0.16 1.06 1.35 1.17 +26.0%
Capex (0.08) (0.07) (0.17) (0.12) (0.05) (0.18) (0.20) (0.05) (0.04) (0.16) +7.2%
Free cash flow 0.06 0.23 0.14 0.38 0.31 (0.26) (0.05) 1.01 1.31 1.01 +36.5%
Book value 2.33 2.75 3.10 3.60 3.78 4.03 4.45 5.20 5.11 6.53 +12.1%
Shares, m 8 8 8 8 9 8 8 9 8 8 +0.1%
Valuation, ×
Valuation, × P/E 20.48 23.48 22.04 31.41 40.32 34.43 28.18 23.58 24.99 30.88 28.0
P/S 1.75 1.57 1.40 3.98 2.70 1.96 1.89 2.21 2.90 4.74 2.5
P/B 2.37 1.96 1.71 4.28 2.98 2.39 2.41 2.72 4.30 6.48 3.2
EV/Sales 1.58 1.38 1.19 3.70 2.40 1.79 1.76 1.94 2.68 4.48 2.3
EV/FCF 80.86 20.88 30.95 37.28 32.69 (33.76) (210.50) 12.25 15.49 39.49 2.6
Cash, $m
Cash, $m Operating cash flow 1 2 3 4 3 (1) 1 9 11 10 +26.2%
Capex (1) (1) (1) (1) 0 (2) (2) 0 0 (1) +7.3%
Free cash flow 1 2 1 3 3 (2) 0 9 11 8 +36.6%
Balance, $m
Balance, $m Working capital 16 18 21 25 27 27 30 36 35 45 +12.5%
Net debt (4) (6) (8) (10) (12) (8) (7) (16) (15) (20) +18.5%
Shareholders’ equity 19 23 26 30 32 34 38 45 43 54 +12.3%
Returns, %
Returns, % ROA 10.22 7.26 6.97 13.28 6.71 5.87 7.26 10.51 14.22 18.82 +8.6 pt
ROIC 15.24 10.44 9.85 16.12 9.56 7.14 8.27 14.45 21.62 25.87 +10.6 pt
ROE 12.59 8.79 8.20 14.86 7.54 6.92 8.81 12.53 17.18 23.26 +10.7 pt
People
People Employees 115 132 119 120 132 156 170 174 180 197 +6.2%
Revenue/emp, $m 0.22 0.21 0.26 0.27 0.27 0.27 0.28 0.31 0.36 0.37 +5.8%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Jun 2026 · latest quarter Jun 2026

Electromed, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
INFU InfuSystems Holdings, Inc. $270.1M 32.0× 33.0× +2.59% (above 0%: growing) +33.33% (above 0%: growing) −66.54% (below 0%: shrinking) 57.98% 11.24% Compare
QSI Quantum-Si Incorporated $256.1M — (loss-making) — (loss-making) −61.59% (below 0%: shrinking) n/m +37.48% (above 0%: growing) 34.91% (11,215.09%) Compare
PROF Profound Medical $251.3M — (loss-making) — (loss-making) +85.86% (above 0%: growing) n/m +47.93% (above 0%: growing) 78.13% (79.56%) Compare
LAB Standard BioTools Inc. $245.7M 1.8× — (loss-making) −0.85% (below 0%: shrinking) n/m +73.32% (above 0%: growing) 55.86% (101.98%) Compare
ELMD Electromed, Inc. $221.8M 19.4× 18.6× +11.64% (above 0%: growing) +57.69% (above 0%: growing) −25.15% (below 0%: shrinking) 78.71% 19.70%
TLSI TriSalus Life Sciences, Inc. $217.4M — (loss-making) — (loss-making) +1.73% (above 0%: growing) n/m −41.29% (below 0%: shrinking) 86.78% (86.03%) Compare
RXST RxSight, Inc. $190.4M — (loss-making) — (loss-making) −18.97% (below 0%: shrinking) n/m +2,591.06% (above 0%: growing) 73.62% (75.32%) Compare
STIM Neuronetics, Inc. $185.2M — (loss-making) — (loss-making) +12.51% (above 0%: growing) n/m +237.71% (above 0%: growing) 52.17% 1.29% Compare
INGN Inogen, Inc $179.7M — (loss-making) — (loss-making) +3.04% (above 0%: growing) n/m −51.15% (below 0%: shrinking) 45.51% (5.36%) Compare
Median of peers $231.5M — — +2.16% — +42.71% 56.92% (77.44%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 29 September 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2026 1.81m 4.27m 394.96
2025 1.49m 4.85m 205.32
2024 3.00m 4.40m 140.34

Ownership

Directors and executive officers, together 11.00%
Stephen H. Craney 7.20%
Dr. George H. Winn 6.00%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Electromed, Inc. (ELMD) Latest News

27 Oct

Impact 3 · · Business Wire

3 Sep

Impact 3 ·

1 Sep

Impact 3 · · The Motley Fool transcript

26 Aug

Impact 4 · transcript
Impact 3 · · Moby transcript

25 Aug

Impact 4 ·
Impact 3 ·
Impact 3 ·

15 May

Impact 3 · · Zacks

14 May

Impact 4 · · Zacks

13 May

Impact 4 · · GuruFocus.com

12 May

Impact 4 · · Zacks
Impact 4 · · Business Wire

5 Apr

Impact 3 · · Simply Wall St.

3 Mar

Impact 4 · · Insider Monkey

2 Mar

Impact 3 · · Zacks

12 Feb

Impact 4 · · GuruFocus.com
Impact 4 · · Zacks

11 Feb

Impact 4 · · Moby transcript

10 Feb

Impact 4 · · Zacks
Impact 4 · · Business Wire

7 Jan

Impact 3 · · Zacks

1 Dec

Impact 4 · · ZacksZacksZacksZacksZacks
Impact 4 · · Zacks

20 Nov

Impact 3 · · Newsfile

17 Nov

Impact 4 · · Zacks

16 Nov

Impact 4 · · Simply Wall St.

14 Nov

Impact 4 · · ZacksZacksZacksZacksZacks
Impact 4 · · Zacks
Impact 4 · · Zacks
stockrow.com/ELMD · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com